April 2026
This quarter’s update is especially meaningful for everyone at EicOsis.
At the beginning of the year, we lost Dr. Bruce Hammock, an extraordinary scientist, mentor, and the founder and Chair of EicOsis. Bruce’s work reshaped how the scientific community understands inflammation and pain, and his vision is the reason this company exists. Just as importantly, his integrity, curiosity, and rigor shaped the culture we continue to carry forward.
This newsletter is dedicated to Bruce’s legacy, not as a look back, but as a reaffirmation. Our mission is clear, our science is strong, and our commitment to execution has only grown stronger. We are grateful to our collaborators, investors, and broader community for your continued trust and support as we move forward, carrying Bruce’s vision into the next chapter of EicOsis.
In this newsletter:
-
IN THIS NEWSLETTER
- Industry Analysis
- Financial Summary
- Potential Indications
- Clinical Update
- Upcoming Milestones
- What’s Next…
April 2025
This quarter marked a defining moment for EicOsis. With the launch of our collaboration with The Michael J. Fox Foundation (MJFF) to develop Parkinson’s disease as an indication, we are officially stepping into a broader role as a neuroinflammation company. In this newsletter, we are excited to share the story of how EicOsis has evolved into a leading CNS therapeutics company, advancing toward the clinic with groundbreaking science.
In this newsletter:
- Industry Analysis: Shifting Investment Trends in Q1 2025
- Financial Update: Stability Amid Industry Shifts
- Our Science: From a Butterfly to PD
- Future Indications
- Our Clinical Journey Continues
- What’s next…
January 2025
2024 has been a breakout year for EicOsis. From being recognized as one of Pepperdine University’s Most Fundable Companies to wrapping up successful Phase 1 trials for our groundbreaking leading compound, we are at the forefront of tackling pain without the risks of opioids. With growing investor interest in neuroinflammation and our trailblazing advances in sEH inhibition, we’re uniquely poised to redefine pain management and neuroinflammatory therapies.
Don’t miss this moment. Explore how we’re transforming science into solutions—and why now is the perfect time to join our journey.
In this newsletter:
- Our Industry: Investment in Pharma is booming
- Our Science: Understanding more of the potential for sEH inhibitors in collaboration with the best research institutions
- Our Progress: Tolerance, Pharmacokinetic, and safety details
- Our Finance: Runway and fundraising updates
